Compare NVEC & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVEC | BWAY |
|---|---|---|
| Founded | 1989 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.2M | 410.4M |
| IPO Year | 1996 | 2019 |
| Metric | NVEC | BWAY |
|---|---|---|
| Price | $64.70 | $21.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | 59.8K | ★ 119.6K |
| Earning Date | 01-21-2026 | 03-10-2026 |
| Dividend Yield | ★ 6.32% | N/A |
| EPS Growth | N/A | ★ 213.09 |
| EPS | ★ 2.92 | 0.13 |
| Revenue | $25,946,127.00 | ★ $49,094,000.00 |
| Revenue This Year | N/A | $330.76 |
| Revenue Next Year | N/A | $22.24 |
| P/E Ratio | ★ $21.67 | $67.54 |
| Revenue Growth | 1.00 | ★ 27.08 |
| 52 Week Low | $51.50 | $7.84 |
| 52 Week High | $82.30 | $25.65 |
| Indicator | NVEC | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 42.94 | 46.06 |
| Support Level | $72.94 | $20.34 |
| Resistance Level | $82.30 | $25.65 |
| Average True Range (ATR) | 3.08 | 1.38 |
| MACD | -0.94 | -0.53 |
| Stochastic Oscillator | 8.56 | 20.90 |
NVE Corp develops and sells devices that use spintronics, a nanotechnology that relies on electron spin. It manufactures high-performance spintronic products including sensors and couplers that are used to acquire and transmit data. The company's products include Digital sensors, Medical sensors, Rotation Sensors, GT Sensors, Angle Sensors, Analog sensors, MSOP Isolators, Passive-In Transceivers, and others. The company manufactures high-performance spintronic products including sensors and couplers. The company's designs are based on giant magnetoresistance GMR and tunneling magnetoresistance TMR combined with integrated circuitry.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.